Source comparison
CJC-1295 Receptor Pharmacology: Research Comparison
This table compares receptor-level characteristics of CJC-1295 to other growth hormone secretagogues commonly used in metabolic research. Understanding these differences is critical for protocol design. Peptides with similar outcomes (elevated IGF-1) achieve t
This comparison does not assign a generated winner or score.
- This table compares receptor-level characteristics of CJC-1295 to other growth hormone secretagogues commonly used in metabolic research. Understanding these differences is critical for protocol design. Peptides with similar outcomes (elevated IGF-1) achieve them through entirely different receptor systems.
- CJC-1295 (with DAC)
- GHRH receptor (GHRHR)
- Class B GPCR
- 6–8 days
- Amplifies endogenous GH pulse amplitude via sustained receptor occupancy
- Best for protocols requiring stable IGF-1 elevation without frequent dosing. Mimics physiological rhythm
- Modified GRF 1-29 (CJC-1295 no DAC)
- 30 minutes
- Acute receptor activation identical to endogenous GHRH
- Requires multiple daily administrations. Useful when transient GH elevation is preferred
- Ipamorelin
- Ghrelin receptor (GHS-R1a)
- Class A GPCR
- 2 hours
- Direct stimulation independent of GHRH; no desensitization at therapeutic doses
- Produces discrete GH pulses. Can be stacked with GHRH analogs for synergistic effect
- GHRP-2
- 20 minutes
- High-affinity GHS-R1a agonist; stimulates appetite via hypothalamic receptors
- Stronger single-dose GH response but increases cortisol and prolactin at higher doses
- MK-677 (Ibutamoren)
- 24 hours
- Oral bioavailability; continuous low-level receptor activation
- Convenient but continuous stimulation may blunt pulsatile rhythm over time
- CJC-1295 receptor pharmacology is the only approach on this list that preserves ultradian rhythm while extending the duration of receptor engagement. Ghrelin receptor agonists (ipamorelin, GHRP-2, MK-677) work through an entirely different receptor system. They don't amplify GHRH signaling; they bypass it. Stacking CJC-1295 with a ghrelin receptor agonist produces additive effects because the two pathways converge at the somatotroph level but are initiated by distinct receptor mechanisms.